New Analyses Advance Understanding of Long-Term Survival Outcomes with Mogamulizumab in Mycosis Fungoides and Sézary Syndrome
PRINCETON, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- Researchers at the World Congress of Cutaneous Lymphoma 2026 presented two indirect treatment comparison (ITC) analyses examining the impact of mogamulizumab on long-term outcomes, including overall survival (OS), in patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL). These findings, which drew on clinical trial and real-world data, expand the growing body of ev
PRINCETON, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- Researchers at the World Congress of Cutaneous Lymphoma 2026 presented two indirect treatment comparison (ITC) analyses examining the impact of mogamulizumab on long-term outcomes, including overall survival (OS), in patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL). These findings, which drew on clinical trial and real-world data, expand the growing body of evidence supporting mogamulizumab use and address critical information gaps where comparative survival data have been limited. The research was funded by Kyowa Kirin Co. Ltd (TSE: 4151).
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.